German based biotechnology company BioNTech SE (BNTX) says it is ready to expand its production capacity in terms of setting up new production facilities if the demand of their COVID-19 vaccine shoots up necessitating for capacity expansion.
The company’s chief financial officer Sierk Poetting said the company is very much willing to construct new production plants but this will have to emanate from increasing demand of the COVID-19 vaccine it developed in collaboration with United States pharmaceutical company Pfizer Inc. (PFE).
“There is still room for improvement. But that will ultimately also depend on demand,” said the CFO during an interview with the Handelsblatt newspaper.
In addition, the CFO said if sites for establishing new plants are available the company can set up addition production plants in six months further saying there are ongoing negotiations on the same and they are making a lot of enquiries on the issue also.
The company is looking forward to produce 2.4 billion COVID-19 vaccines this year out which 1.4 billion are already booked. BioNTech said it will scale up production to 3 billion COVID-19 vaccines next year.
